Payment overview · 2025
General Payments
$544.84
25 reported records · 12 companies
Healthcare provider profile · identity verified
Sharnjit Purewal, MD
Allopathic & Osteopathic Physicians|Family Medicine · CLOVIS, CA · NPI 1740251818
Verified facts
What the public records show
CMS Open Payments records show Sharnjit Purewal, MD received $544.84 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $122.17 | 22.4% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.54 | 11.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.96 | 10.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $58.75 | 10.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.06 | 9.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $39.73 | 7.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.90 | 6.8% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $30.54 | 5.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $29.82 | 5.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.31 | 3.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.79 | 3.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.27 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $544.84 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $113.60 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $90.34 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $58.96 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $58.75 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $36.90 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.83 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $29.82 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 83 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 612 | 222 |
| Levothyroxine Sodium | Levothyroxine Sodium | 454 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 373 | 129 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 327 | 61 |
| Lisinopril | Lisinopril | 317 | 121 |
| Metformin Hcl | Metformin Hcl | 313 | 105 |
| Gabapentin | Gabapentin | 264 | 78 |
| Omeprazole | Omeprazole | 231 | 97 |
| Losartan Potassium | Losartan Potassium | 228 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 214 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 184 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 124 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 123 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 114 | 32 |
| Tramadol Hcl | Tramadol Hcl | 105 | 31 |
| Trazodone Hcl | Trazodone Hcl | 103 | 31 |
| Meloxicam | Meloxicam | 101 | 39 |
| Pregabalin | Pregabalin | 96 | 23 |
| Ezetimibe | Ezetimibe | 91 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 89 | 31 |
| Famotidine | Famotidine | 87 | 34 |
| Myrbetriq | Mirabegron | 87 | 20 |
| Furosemide | Furosemide | 86 | 39 |
| Jardiance | Empagliflozin | 83 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 24 |
| Finasteride | Finasteride | 76 | 29 |
| Sertraline Hcl | Sertraline Hcl | 76 | 24 |
| Potassium Chloride | Potassium Chloride | 74 | 30 |
| Eliquis | Apixaban | 72 | 23 |
| Glimepiride | Glimepiride | 71 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 27 |
| Simvastatin | Simvastatin | 69 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 25 |
| Donepezil Hcl | Donepezil Hcl | 66 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 18 |
| Allopurinol | Allopurinol | 65 | 29 |
| Baclofen | Baclofen | 65 | 21 |
| Alendronate Sodium | Alendronate Sodium | 64 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 17 |
| Alprazolam | Alprazolam | 57 | 17 |
| Trulicity | Dulaglutide | 55 | 12 |
| Ozempic | Semaglutide | 54 | 16 |
| Montelukast Sodium | Montelukast Sodium | 53 | 24 |
| Valsartan | Valsartan | 50 | 17 |
| Prednisone | Prednisone | 49 | 19 |
| Atenolol | Atenolol | 48 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 12 |
| Carvedilol | Carvedilol | 47 | 19 |
| Metformin Hcl Er | Metformin Hcl | 46 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 28 |
| Spironolactone | Spironolactone | 45 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 44 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 15 |
| Januvia | Sitagliptin Phosphate | 43 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Ibuprofen | Ibuprofen | 41 | 15 |
| Naproxen | Naproxen | 40 | 14 |
| Ramipril | Ramipril | 40 | 13 |
| Topiramate | Topiramate | 40 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | 11 |
| Lorazepam | Lorazepam | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Novolog Flexpen | Insulin Aspart | 33 | 11 |
| Celecoxib | Celecoxib | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 28 | 28 |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 25 |
| Clonidine Hcl | Clonidine Hcl | 27 | 11 |
| Lovastatin | Lovastatin | 27 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 21 |
| Tradjenta | Linagliptin | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 24 |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Estradiol | Estradiol | 23 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 17 |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 18 |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nucynta | Tapentadol Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $544.84 · 25 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, EVENITY, FREESTYLE LIBRE 3, JARDIANCE, LEQVIO, OTEZLA, Ozempic, PROLIA, REPATHA, REXULTI, SHINGRIX, VOQUEZNA, VRAYLAR | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error